(2010) Treatment of Her2-Positive Breast Cancer: What’s on the Horizon. Current Breast Cancer Reports 2 , 42-52 /Windy Dean-Colomb, Francisco J. Esteva. (2010) Treatment of Her2-Positive Breast Cancer: What’s on the Horizon. Current Breast Cancer Reports 2 , 42-52 /...
Sara A. Hurvitz, MD, comments on her preferences for treating patients with HER2-positive metastatic breast cancer and shares her strategy for sequencing therapies.
use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer. ...
"The introduction of anti-HER2 therapies has brought a hugesurvival benefitin early and advanced HER2 positive breast cancer, thus there is now a need for reducing the intensity and side effects of thetreatmentadministered," said Criscitiello. "However, the priority is to identify whichpatientsmig...
HER2-positive breast cancer is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. Approximately one of every five breast cancers have a gene mutation in the cancer cells...
Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH (2009) Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann... S Kilickap,C Arslan - 《Annals of Oncology》 被引量: 123发表: 2009年 Treatment of HER2-Positive Metastatic Breast Cancer Following Initi...
Breast Cancer: Targets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients Review This article was published in the following Dove Press journal: Breast ...
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were tr
HER2+ breast cancer is one of the most aggressive forms of breast cancer. The new polymalic acid-based mini nanodrug copolymers are synthesized and specifically characterized to inhibit growth of HER2+ breast cancer. These mini nanodrugs are highly effective and in the clinic may substitute for ...
Cancer Network: Dr. Pegram, what are the current HER2 therapies available for treatment of women with HER2-positive breast cancer? Dr. Pegram: Since 1998, we have had trastuzumab, which has become the mainstay of HER2-targeted breast cancer therapies for both advanced ca...